CPT1A and cancer: Another recent study found that CPT1 contributes to antiangiogenic drug resistance, and that inhibition CPT1 significantly compromises free fatty acid (FFA)-induced cell proliferation using a variety of cancer types, including colorectral cancer and hepatocellular carcinoma cells [39].